Analyst consensus rating
Actuate Therapeutics Analyst Rating: Strong Buy
ACTU is rated Strong Buy by 4 analysts with a $10.01 target. As of 2026-08-24.
Direct answer
Actuate Therapeutics's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.01.
Forecast evidence checked August 24, 2026.
Get free Actuate Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.22
- Average price target
- $10.01
- High price target
- $15.05
- Low price target
- $5.00
- Low target gap
- +311.5%
- Target upside
- +724.1%
- High target gap
- +1,138.7%
- Target range width
- 827.2%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Actuate Therapeutics?
Actuate Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $10.01.
How far are Actuate Therapeutics's low and high targets from the recorded price?
The low target implies +311.5%, while the high target implies +1,138.7%.
How many analysts are included in Actuate Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Actuate Therapeutics's target upside or downside calculated?
The average target of $10.01 is divided by the recorded price of $1.22, then one is subtracted to produce +724.1%. This does not guarantee a future return.
When was Actuate Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.